| Literature DB >> 31743333 |
Ahrong Kim1, So Jeong Lee1, Jihyun Ahn2, Won Young Park1, Dong Hoon Shin3, Chang Hun Lee1, Hoon Kwon4, Yeon Joo Jeong4, Hyo Yeong Ahn5, Hoseok I5, Yeong Dae Kim5, Jeong Su Cho5.
Abstract
The prognostic significance of tumor-infiltrating lymphocytes has been determined in cancers of the lung, colon and breast, though there is no standardized method for using this prognostic indicator for lung cancer. We applied a modified version of the method proposed by the International Immuno-Oncology Biomarkers Working Group to primary lung adenocarcinoma, which uses histologic findings of hematoxylin and eosin sections. The study included a total cohort of 146 lung adenocarcinoma patients who underwent lobectomy with lymph node dissection at two hospitals between 2008 and 2012. The full-face sections of hematoxylin and eosin-stained slides were reviewed, and we evaluated the level of tumor-infiltrating lymphocytes as a percentage of the area occupied out of the total intra-tumoral stromal area. Histopathologic factors include histologic grade, necrosis, extracellular mucin, lymphovascular invasion, lymph node metastasis, level of tumor infiltrating lymphocytes, tertiary lymphoid structures around the tumor, and the presence of a germinal center in tertiary lymphoid structures. The high level of tumor-infiltrating lymphocytes was found to be significantly correlated with the histologic grade (p = 0.023), necrosis (p = 0.042), abundance of tertiary lymphoid structures(p<0.001) and presence of a germinal center in tertiary lymphoid structures (p = 0.004). A high level of tumor-infiltrating lymphocytes was associated with better progression-free survival (p = 0.011) as well as overall survival (p = 0.049). On multivariable analysis, high tumor-infiltrating lymphocyte levels were a good independent prognostic factor for progression-free survival (Hazard ratio: 0.389, 95% confidence interval: 0.161-0.941, p = 0.036). Histologic evaluation of tumor-infiltrating lymphocytes level in lung adenocarcinoma with H&E sections therefore has prognostic value in routine surgical pathology.Entities:
Year: 2019 PMID: 31743333 PMCID: PMC6863614 DOI: 10.1371/journal.pone.0224430
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Assessment of tumor-infiltrating lymphocytes (TILs) level.
(A) 5% of TILs (x200) (B) 20% of TILs (x200) (C) 60% of TILs (x200) (D) 80% of TILs (x200) (E) Area with aerosol spread was excluded. (x200) (F) Area with lepidic growth pattern was not included in assessment of TILs. (x200).
Fig 2Assessment of tertiary lymphoid structures (TLSs).
(A) Yellow colored arrow head indicates TLSs without germinal center around invasive tumor. (x40) (B) Blue colored arrow head indicates TLS with germinal center around invasive tumor (x40) and inset shows the magnified image of TLS (x200) (C) Absence of TLSs around invasive tumor (x12.5) (D) Abundant TLSs with germinal center (red asterick) around invasive tumor (x12.5).
Basic data of primary lung adenocarcinoma.
| Characteristic | Number (%) |
|---|---|
| Age, mean ± SD | 63.730 ± 10.176 years |
| Size, mean ± SD | 2.820 ± 1.319 cm |
| Smoking history | |
| Never-smoker | 85 (58.2) |
| Smoker | 61 (41.8) |
| Histologic grade | |
| Well differentiated | 111 (76.0) |
| Moderately differentiated | 27 (18.5) |
| Poorly differentiated | 8 (5.5) |
| Necrosis in tumor | |
| Absent | 109 (74.7) |
| Present | 37 (25.3) |
| Extracellular production | |
| Absent | 123 (84.2) |
| Present | 23 (15.8) |
| Lymphovascular invasion | |
| Absent | 121 (82.9) |
| Present | 25 (17.1) |
| Lymph node metastasis | |
| Absent | 111 (76.0) |
| Present | 35 (24.0) |
| Stage (AJCC 7th edition) | |
| I | 95 (65.1) |
| II | 25 (17.1) |
| III | 13 (8.9) |
| IV | 13 (18.9) |
| Tumor infiltrating lymphocytes | |
| Low (<50%) | 113 (77.4) |
| High (≥ 50%) | 33 (22.6) |
| Tertiary lymphoid structures around tumor | |
| Absent | 89 (61.0) |
| Present | 57 (39.0) |
| Tertiary lymphoid structures around tumor | |
| Low | 106 (72.6) |
| High | 40 (27.4) |
| Germinal center in tertiary lymphoid structures | |
| Absent | 129 (88.4) |
| Present | (11.6) |
* except for age and sizes. SD, standard deviation.
Clinicopathologic correlation according to level of TILs.
| Low TILs level | High TILs level | ||
|---|---|---|---|
| Age | 64.170±10.350 | 62.210±9.552 | 0.333 |
| Size (cm) | 2.872±1.352 | 2.672±1.207 | 0.446 |
| Smoking history | 0.231 | ||
| Never-smoker | 69 (61.1%) | 16 (48.5%) | |
| Smoker | 44 (38.9%) | 17(51.5%) | |
| Histologic grade | |||
| Well differentiated | 91 (80.5%) | 20 (60.6%) | |
| Moderately differentiated | 18 (15.9%) | 9 (27.3%) | |
| Poorly differentiated | 4 (3.5%) | 4 (12.1%) | |
| Necrosis | |||
| Absent | 89 (78.8%) | 20 (60.6%) | |
| Present | 24 (21.2%) | 13 (39.4%) | |
| Extracellular mucin production | 0.786 | ||
| Absent | 96 (85.0%) | 27 (81.8%) | |
| Present | 17 (15.0%) | 6 (18.2%) | |
| Lymphovascular invasion | 0.067 | ||
| Absent | 90 (79.6%) | 31 (93.9%) | |
| Present | 23 (20.4%) | 2 (6.1) | |
| Lymph node metastasis | 0.103 | ||
| Absent | 82 (72.6%) | 29 (87.9%) | |
| Present | 31 (27.4%) | 4 (12.1%) | |
| Stage | 0.196 | ||
| Early (stage I and II) | 90 (79.6%) | 30 (90.9%) | |
| Advanced (stage III and IV) | 23 (20.4%) | 3 (9.1%) | |
| TLSs | |||
| Absence | 81 (71.7) | 8 (24.2) | |
| Presence | 32 (28.3) | 25 (75.8) | |
| TLSs around tumor | |||
| Low | 97 (85.8%) | 9 (27.3%) | |
| High | 16 (14.2%) | 24 (72.7%) | |
| Germinal center in TLSs | |||
| Absent | 105 (92.9%) | 24 (72.7%) | |
| Present | 8 (7.1%) | 9 (27.3%) | |
| EGFR | |||
| No data | 6 | 5 | |
| Absent | 48 (44.9%) | 14 (50.0%) | 0.627 |
| Present | 59 (55.1%) | 14 (50.0%) | |
| KRAS mutation | |||
| No data | 7 | 5 | |
| Absent | 92 (86.8%) | 24 (85.7%) | 0.868 |
| Present | 14 (13.1%) | 4 (14.3%) |
* except for age and sizes.
** t-test was performed and the equality of variances was assumed. SD, standard deviation. The Pearson’s Chi-square test or Fisher’s exact test was used as appropriate for the other variables. EGFR and KRAS mutation was detected by pyrosequencing.
+TILs, tumor-infiltrating lymphocytes
++TLSs, tertiary lymphoid structures
+++EGFR, epidermal growth factor receptor
Fig 3Survival analysis in resected lung adenocarcinoma.
(A) Overall survival according to tumor-infiltrating lymphocytes (TILs) level (B) Progression-free survival according to TILs level (C) Overall survival according to TILs level in early stage (stage I and II) disease (D) Overall survival according to TILs level in advanced stage (stage III and IV) disease (E) Progression-free survival according to TILs level in early stage (stage I and II) disease (F) Progression-free survival according to TILs level in advanced stage (stage III and IV) disease.
Univariate and multivariable analyses of overall survival and progression free survival.
| Overall survival | Progression free survival | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Univariate analysis | Multivariable analysis | |||||||
| HR | 95% CI | HR | 95% CI | HR | 95% CI | ||||
| Age | 1.381 | 0.438–4.355 | 0.581 | 1.443 | 0.843–2.470 | 0.181 | |||
| Histologic grade | 0.773 | 0.168–3.550 | 0.741 | 2.286 | 1.301–4.018 | 2.034 | 1.105–3.743 | ||
| Lymphovascular invasion | 5.300 | 1.652–17.004 | 4.901 | 2.767–8.681 | 2.752 | 1.369–5.531 | |||
| Stage | 7.009 | 2.210–22.228 | 5.197 | 2.970–9.094. | 2.627 | 1.323–5.216 | |||
| TILs | 0.032 | 0.000–8.784 | 0.230 | 0.353 | 0.151–0.825 | 0.389 | 0.161–0.941 | ||
*Multivariable analysis was performed with covariables showing p-value of less than 0.10 in the univariate analyses for multivariable analysis.
**The likelihood ratio test was done to ensure the proportional hazard assumptions in the Cox regression model.
+HR, hazard ratio
++CI, confidence interval
+++TILSs, tumor-infiltrating lymphocytes